What the studies show
Mostly mild-to-moderate nausea and vomiting, easing over time; the profile reported as consistent with GLP-1 drugs.
Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.
- 1Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1).N Engl J Med, 2025; DOI 10.1056/NEJMoa25020813,417 adults, 68 weeks, four arms.
In context
Cagrilintide is a once-weekly analogue of amylin, a hormone the pancreas releases alongside insulin that signals fullness. On its own it produced about 12% weight loss over 68 weeks; combined with semaglutide as CagriSema it produced 22.7% in a 3,417-person phase 3 trial published in the New England Journal of Medicine. Neither is approved yet, and the combination missed the 25% figure its developer had signalled.
Cagrilintide is investigational. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Cagrilintide proven to cause GI side effects?
What studies are behind the grade?
Is Cagrilintide approved for this?
Other outcomes for Cagrilintide
- BBody weight (with semaglutide, CagriSema)1 large phase 3 RCT
- BBody weight (alone)Phase 2 + phase 3 arm
Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →